Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors
07 juin 2023 07h30 HE
|
Entera Bio Ltd.
JERUSALEM, June 07, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Announces Q1 2023 Financial Results and Corporate Updates
05 mai 2023 16h05 HE
|
Entera Bio Ltd.
JERUSALEM, May 05, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera’s Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics
03 mai 2023 09h34 HE
|
Entera Bio Ltd.
JERUSALEM, May 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Menopause Luminary, Dr. Steven R. Goldstein, Joins Entera’s Clinical and Scientific Advisory Board
26 avr. 2023 08h30 HE
|
Entera Bio Ltd.
JERUSALEM, April 26, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program
03 avr. 2023 07h00 HE
|
Entera Bio Ltd.
JERUSALEM, April 03, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022
31 mars 2023 16h00 HE
|
Entera Bio Ltd.
JERUSALEM, March 31, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...
Entera Bio Regains Compliance with Nasdaq Listing Requirements
23 mars 2023 09h27 HE
|
Entera Bio Ltd.
JERUSALEM, March 23, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced...
Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis
15 févr. 2023 10h00 HE
|
Entera Bio Ltd.
Type D meeting protocol submission builds on concurrence reached with FDA following successful Type C meeting and supports potential Phase 3 initiation in H2 2023 JERUSALEM, Feb. 15, 2023 (GLOBE...
Entera Bio to Participate in the SVB Securities Global Biopharma Conference
13 févr. 2023 09h00 HE
|
Entera Bio Ltd.
JERUSALEM, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a late-clinical stage, leader in the development of orally delivered peptides and therapeutic...
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
10 nov. 2022 16h15 HE
|
Entera Bio Ltd.
JERUSALEM, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today...